Particle Therapy Market by Type, Products, Services, System, Cancer Type, Application - Forecast to 2023 - ResearchAndMarkets.com

DUBLIN--()--The "Particle Therapy Market by Type, Products, Services, System, Cancer Type, Application - Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%

The growth of this market is largely driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.

The cyclotrons segment is expected to account for the largest market share during the forecast period

Based on type, the particle therapy products market is segmented into cyclotrons, synchrotrons, and synchrocyclotrons. The cyclotrons segment is expected to account for the largest share of this market in 2018. The development of technologically advanced systems, advantages offered by cyclotrons over other accelerators, and the growing adoption of cyclotrons among users are the major factors driving the growth of this market segment.

The research applications segment is estimated to grow at the highest rate during the forecast period

On the basis of application, the particle therapy market has been segmented into treatment and research applications. The research applications segment is estimated to grow at the highest rate during the forecast period due to factors such as the growing awareness about the research applications of particle therapy systems, development of cost-effective and technologically advanced diagnostic and therapeutic particle therapy systems, and the increasing industry-academia collaborations in the field of research.

North America to account for the second-largest share of the global market in 2018

The particle therapy market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. North America is expected to account for the second-largest share of the global particle therapy market in 2018. Technological advancements in the field of particle therapy, the rising incidence of cancer, easy accessibility to treatments, and the high adoption of advanced diagnostic technologies (owing to the significant per capita annual healthcare expenditure by the US and Canadian governments) are some of the key factors supporting the growth of the North American market.

Furthermore, favorable government initiatives that are creating awareness and promoting the adoption of proton therapy among key end users are some of the other major factors driving the growth of the particle therapy market in North America.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Particle Therapy Market, By Type

7 Particle Therapy Market, By Product & Service

8 Particle Therapy Market, By System

9 Particle Therapy Market, By Cancer Type

10 Particle Therapy Market, By Application

11 Particle Therapy Market, By Region

12 Competitive Landscape

13 Company Profiles

  • Advanced Oncotherapy PLC.
  • Danfysik A/S
  • Hitachi, Ltd.
  • Ion Beam Applications Sa (IBA)
  • Mevion Medical Systems, Inc.
  • Optivus Proton Therapy, Inc.
  • Protom International, Inc.
  • Provision Healthcare, LLC
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/v2pgtj/particle_therapy?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Oncology Drugs